Jinwon Life Sciences announced on the 13th that it has signed a plasmid DNA pharmaceutical supply contract worth 3.7 million dollars with a US-based biotech company.
The contracting party cannot be disclosed due to a confidentiality clause, but it is a company developing antibody-drug conjugates (ADC). The contract amount is approximately 5 billion KRW when converted to Korean won.
Park Young-geun, CEO of Jinwon Life Sciences, said, "This supply contract involves producing plasmid DNA using the largest 1500-liter fermenter installed in the new factory, serving as an opportunity to demonstrate our capability to supply large-scale, high-quality plasmid DNA," and added, "We will continue to actively expand our sales activities to significantly increase revenue through large-scale production."
Jinwon Life Sciences operates a contract development and manufacturing organization (CDMO) business that produces and supplies high-quality plasmid DNA at its subsidiary VGXI’s new factory located in Davidson Technology Park, Conroe, Texas, USA.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
